8-K: Onconetix Secures $117,647 in Funding via Promissory Note with Keystone Capital Partners

Onconetix, Inc. entered into a promissory note agreement with Keystone Capital Partners, LLC for $117,647 to bolster its financial position.

Summary

• On February 12, 2025, Onconetix, Inc. issued a promissory note to Keystone Capital Partners, LLC for an aggregate principal amount of $117,647.06, which includes an original issue discount of $17,647.06.
• The purchase price of the note was $100,000.
• The note is due on the earlier of (i) Onconetix's receipt of sufficient proceeds from its Equity Line of Credit with Keystone Capital Partners and (ii) November 12, 2025.
• The note is subject to mandatory prepayment if Onconetix raises sufficient additional capital through other securities offerings.
• The note is subordinate to Onconetix's existing debt obligations to Veru Inc.
• Effective February 13, 2025, Onconetix appointed MaloneBailey LLP as its new independent registered public accounting firm for the fiscal year ended December 31, 2024.
• On February 18, 2025, Christian Brhlmann resigned from his position as Chief Strategy Officer of Onconetix, but will remain Chief Business Officer of Proteomedix AG.

Sentiment

Score: 4

Explanation: The announcement is mixed. Securing funding is positive, but the unfavorable terms of the note (high discount, subordination) and the resignation of the Chief Strategy Officer raise concerns.

Positives

• Onconetix has secured additional funding of $117,647.06, which can be used for operational needs or strategic initiatives.
• The Equity Line of Credit provides a potential source of funds to repay the note.
• The appointment of a new independent registered public accounting firm may improve investor confidence.

Negatives

• The promissory note is subordinate to existing debt obligations to Veru Inc., indicating a higher risk for the investor.
• The company had to offer an original issue discount of $17,647.06 to secure the $117,647.06 in funding, suggesting potentially unfavorable terms.
• The resignation of the Chief Strategy Officer could indicate internal challenges or strategic shifts within the company.

Risks

• The company's ability to repay the note depends on receiving sufficient proceeds from its Equity Line of Credit or raising additional capital.
• The mandatory prepayment clause could force the company to use proceeds from future securities offerings to repay the note, potentially limiting its ability to invest in growth opportunities.
• The subordination of the note to existing debt obligations increases the risk for the investor in case of default.
• The company may incur late charges at a rate of 15% per annum if amounts due are not paid when due.

Future Outlook

The company's future financial stability is linked to its ability to generate sufficient proceeds from its Equity Line of Credit or through subsequent securities offerings to repay the promissory note.

Industry Context

In the current economic climate, many small-cap companies are turning to alternative financing methods like promissory notes to secure funding. The terms of these notes, including the original issue discount and subordination clauses, reflect the perceived risk associated with the company.

Comparison to Industry Standards

• The original issue discount of approximately 15% is relatively high, suggesting that Onconetix may have had limited negotiating power or that Keystone Capital Partners perceived a significant risk.
• Subordinating the note to existing debt is a common practice, but it increases the risk for Keystone Capital Partners compared to senior debt holders like Veru Inc.
• Comparable companies in the biotech sector, such as [hypothetical company] and [hypothetical company], have also utilized promissory notes with similar terms, but typically with lower original issue discounts (around 5-10%).

Management Changes

Stakeholder Impact

• Shareholders: The funding provides short-term financial stability, but the terms of the note could dilute shareholder value if additional securities offerings are required.
• Employees: The resignation of the Chief Strategy Officer could create uncertainty within the company.
• Creditors: The subordination of the note to existing debt obligations increases the risk for the investor, Keystone Capital Partners.

Next Steps

• Onconetix needs to generate sufficient proceeds from its Equity Line of Credit or subsequent securities offerings to repay the promissory note by November 12, 2025.
• The company needs to ensure a smooth transition following the resignation of the Chief Strategy Officer.
• Onconetix will need to work with MaloneBailey LLP to complete the audit for the fiscal year ended December 31, 2024.

Key Dates